Terms: = Prostate cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4
53 results:
1. Metastatic Lymph Node 64 (MLN64) Expression in Gastric cancer: The Clinical and Molecular Implications in Drug Resistance.
Li AX; Zeng JJ; Khan E; Dou QP; Zhuang X; Ji EK; Ruge F; Martin TA; Jia S; Jiang WG
Cancer Genomics Proteomics; 2024; 21(1):30-40. PubMed ID: 38151289
[TBL] [Abstract] [Full Text] [Related]
2. Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126.
McDonald AM; DeMora L; Yang ES; Hoyle JM; Lenzie A; Williams GR; Michalski JM; Yee D; Bahary JP; Den RB; Roach M; Dess R; Mishra MV; Valicenti RK; Lau HY; Marcrom SR; Souhami L; Mendez LC; Chen Y; Doncals DE; Pugh SL; Feng FY; Sandler HM
Cancer; 2023 Mar; 129(5):685-696. PubMed ID: 36579470
[TBL] [Abstract] [Full Text] [Related]
3. Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant prostate cancer.
Nindra U; Hong JH; Balakrishnar B; Pal A; Chua W
Clin Genitourin Cancer; 2023 Feb; 21(1):183-193. PubMed ID: 35927195
[TBL] [Abstract] [Full Text] [Related]
4. Medicare Accountable Care Organizations: Post-acute Care Use and Post-surgical Outcomes in Urologic cancer Surgery.
Katragadda C; Fung C; Yousefi-Nooraie R; Cupertino P; Joseph J; Kim Y; Li Y
Urology; 2022 Sep; 167():102-108. PubMed ID: 35772480
[TBL] [Abstract] [Full Text] [Related]
5. Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome.
Kretschmer A; Tutrone R; Alter J; Berg E; Fischer C; Kumar S; Torkler P; Tadigotla V; Donovan M; Sant G; Skog J; Noerholm M
World J Urol; 2022 Apr; 40(4):983-989. PubMed ID: 35084544
[TBL] [Abstract] [Full Text] [Related]
6. The Yin and Yang of erbb4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
7. Diagnostic assessment program for prostate cancer: Lessons learned after 2 years and degree of compliance to Canadian guidelines.
Shabana W; Kotb A; Tesolin D; Ibrahim MFK; Dolcetti K; Boucher A; Bassuony M; Ramchandar K; Zakaria AS; Elmansy H; Shahrour W
Arch Ital Urol Androl; 2021 Dec; 93(4):389-392. PubMed ID: 34933523
[TBL] [Abstract] [Full Text] [Related]
8. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract] [Full Text] [Related]
9. Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
[TBL] [Abstract] [Full Text] [Related]
10. The role of erbb4 in cancer.
Segers VFM; Dugaucquier L; Feyen E; Shakeri H; De Keulenaer GW
Cell Oncol (Dordr); 2020 Jun; 43(3):335-352. PubMed ID: 32219702
[TBL] [Abstract] [Full Text] [Related]
11. Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.
Jathal MK; Steele TM; Siddiqui S; Mooso BA; D'Abronzo LS; Drake CM; Whang YE; Ghosh PM
Br J Cancer; 2019 Jul; 121(3):237-248. PubMed ID: 31209328
[TBL] [Abstract] [Full Text] [Related]
12. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
[TBL] [Abstract] [Full Text] [Related]
13. erbb4 gene polymorphisms and the risk of prostate cancer in a sample of Iranian Population.
Hashemi M; Moradi N; Rezaei M; Sanaei S; Ziaee SA; Narouie B; Sotoudeh M; Bahari G; Ghavami S
Cell Mol Biol (Noisy-le-grand); 2016 Aug; 62(10):43-8. PubMed ID: 27609473
[TBL] [Abstract] [Full Text] [Related]
14. Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.
Ocaña A; Díez-González L; Esparís-Ogando A; Montero JC; Amir E; Pandiella A
Oncotarget; 2016 Jul; 7(29):45042-45051. PubMed ID: 27074567
[TBL] [Abstract] [Full Text] [Related]
15. Genome-wide haplotype association study identifies BLM as a risk gene for prostate cancer in Chinese population.
Wang Q; Lv H; Lv W; Shi M; Zhang M; Luan M; Zhu H; Zhang R; Jiang Y
Tumour Biol; 2015 Apr; 36(4):2703-7. PubMed ID: 25472581
[TBL] [Abstract] [Full Text] [Related]
16. HNF1b is involved in prostate cancer risk via modulating androgenic hormone effects and coordination with other genes.
Hu YL; Zhong D; Pang F; Ning QY; Zhang YY; Li G; Wu JZ; Mo ZN
Genet Mol Res; 2013 Apr; 12(2):1327-35. PubMed ID: 23661456
[TBL] [Abstract] [Full Text] [Related]
17. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract] [Full Text] [Related]
18. Heregulin expression and prognosis in prostate adenocarcinoma.
Grimsley SJ; Shini S; Underwood MA; Edwards J
Urol Int; 2011; 87(3):363-8. PubMed ID: 21865659
[TBL] [Abstract] [Full Text] [Related]
19. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.
Chen L; Mooso BA; Jathal MK; Madhav A; Johnson SD; van Spyk E; Mikhailova M; Zierenberg-Ripoll A; Xue L; Vinall RL; deVere White RW; Ghosh PM
Clin Cancer Res; 2011 Oct; 17(19):6218-28. PubMed ID: 21844010
[TBL] [Abstract] [Full Text] [Related]
20. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
Todor DA; Barani IJ; Lin PS; Anscher MS
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
[TBL] [Abstract] [Full Text] [Related]
[Next]
